Literature DB >> 9272582

Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

.   

Abstract

Staphylococcus aureus is one of the most common causes of both hospital- and community-acquired infections worldwide, and the antimicrobial agent vancomycin has been used to treat many S. aureus infections, particularly those caused by methicillin-resistant S. aureus (MRSA). In 1996, the first documented case of infection caused by a strain of S. aureus with intermediate levels of resistance to vancomycin (VISA; minimum inhibitory concentration [MIC]=8 microg/mL) was reported from Japan. This report describes the first isolation of VISA from a patient in the United States, which may be an early warning that S. aureus strains with full resistance to vancomycin will emerge.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272582

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  83 in total

Review 1.  Antibiotic resistance: a current perspective.

Authors:  K F Barker
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

2.  Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital.

Authors:  A Marchese; G Balistreri; E Tonoli; E A Debbia; G C Schito
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.

Authors:  S Boyle-Vavra; S K Berke; J C Lee; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus.

Authors:  J R Aeschlimann; E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Structural and topological differences between a glycopeptide-intermediate clinical strain and glycopeptide-susceptible strains of Staphylococcus aureus revealed by atomic force microscopy.

Authors:  S Boyle-Vavra; J Hahm; S J Sibener; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.

Authors:  Juliette Pavie; Agnès Lefort; Marie-Cécile Ploy; Laurent Massias; Françoise Chau; Louis Garry; François Denis; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

7.  Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance.

Authors:  Susan Boyle-Vavra; Mamatha Challapalli; Robert S Daum
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

8.  Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II.

Authors:  Isabelle Verdier; Marie-Elisabeth Reverdy; Jerome Etienne; Gérard Lina; Michèle Bes; François Vandenesch
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

9.  Analysis of antimicrobial resistance and class 1 integrons among strains from upper respiratory tract of healthy adults.

Authors:  Haiyan Liu; Hai Wang; Mao Huang; Yaning Mei; Bing Gu; Rui Wu; Yiling Huang; Yi Chen; Yanling Xu; Tong Wang
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

10.  Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial.

Authors:  K G Shojania; D Yokoe; R Platt; J Fiskio; N Ma'luf; D W Bates
Journal:  J Am Med Inform Assoc       Date:  1998 Nov-Dec       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.